Massive Intoxication with 70 Tablets of Apixaban: A Case Report

Abstract Apixaban is a direct oral anticoagulation agent that exerts its effect through the direct inhibition of factor Xa. We treated a case of massive intoxication with 70 tablets of apixaban and have presented the clinical course of the associated anti-Xa activities. A 49-year-old woman was admit...

Full description

Saved in:
Bibliographic Details
Published inCase reports in acute medicine Vol. 6; no. 1; pp. 13 - 18
Main Authors Kobayashi, Tadahiro, Saito, Satoko, Takada, Masayuki, Sakaguchi, Kento, Takahashi, Kazunori, Tanaka, Ken, Kawamae, Kaneyuki, Nakane, Masaki
Format Journal Article
LanguageEnglish
Published Basel, Switzerland Karger Publishers 12.09.2023
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Abstract Apixaban is a direct oral anticoagulation agent that exerts its effect through the direct inhibition of factor Xa. We treated a case of massive intoxication with 70 tablets of apixaban and have presented the clinical course of the associated anti-Xa activities. A 49-year-old woman was admitted to the emergency department approximately 1.5 h after impulsive self-intoxication with 175 mg of apixaban. She developed coagulopathy with prothrombin time-international normalized ratio (PT-INR) of 3.65, activated partial thromboplastin time of 56.5 s, and antithrombin activity (AT) of >150% (at 1.5 h post-ingestion). The patient’s initial and peak anti-Xa activity was 17.7 IU/mL, and its elimination displayed first-order kinetics with a half-life of 10.5 h. The patient’s anti-Xa activity was within the therapeutic dose range at 26 h post-ingestion, and she recovered without experiencing any bleeding complications. Her coagulopathy also returned to normal level at the same timing. This result suggests that PT-INR and AT can be used as substitute markers of overwhelmed anticoagulation following massive overdose of apixaban. A case of apixaban overdose with associated anti-Xa activities was presented. There was favorable resolution of anticoagulation without specific treatments.
AbstractList Apixaban is a direct oral anticoagulation agent that exerts its effect through the direct inhibition of factor Xa. We treated a case of massive intoxication with 70 tablets of apixaban and have presented the clinical course of the associated anti-Xa activities. A 49-year-old woman was admitted to the emergency department approximately 1.5 h after impulsive self-intoxication with 175 mg of apixaban. She developed coagulopathy with prothrombin time-international normalized ratio (PT-INR) of 3.65, activated partial thromboplastin time of 56.5 s, and antithrombin activity (AT) of >150% (at 1.5 h post-ingestion). The patient’s initial and peak anti-Xa activity was 17.7 IU/mL, and its elimination displayed first-order kinetics with a half-life of 10.5 h. The patient’s anti-Xa activity was within the therapeutic dose range at 26 h post-ingestion, and she recovered without experiencing any bleeding complications. Her coagulopathy also returned to normal level at the same timing. This result suggests that PT-INR and AT can be used as substitute markers of overwhelmed anticoagulation following massive overdose of apixaban. A case of apixaban overdose with associated anti-Xa activities was presented. There was favorable resolution of anticoagulation without specific treatments.
Abstract Apixaban is a direct oral anticoagulation agent that exerts its effect through the direct inhibition of factor Xa. We treated a case of massive intoxication with 70 tablets of apixaban and have presented the clinical course of the associated anti-Xa activities. A 49-year-old woman was admitted to the emergency department approximately 1.5 h after impulsive self-intoxication with 175 mg of apixaban. She developed coagulopathy with prothrombin time-international normalized ratio (PT-INR) of 3.65, activated partial thromboplastin time of 56.5 s, and antithrombin activity (AT) of >150% (at 1.5 h post-ingestion). The patient’s initial and peak anti-Xa activity was 17.7 IU/mL, and its elimination displayed first-order kinetics with a half-life of 10.5 h. The patient’s anti-Xa activity was within the therapeutic dose range at 26 h post-ingestion, and she recovered without experiencing any bleeding complications. Her coagulopathy also returned to normal level at the same timing. This result suggests that PT-INR and AT can be used as substitute markers of overwhelmed anticoagulation following massive overdose of apixaban. A case of apixaban overdose with associated anti-Xa activities was presented. There was favorable resolution of anticoagulation without specific treatments.
Author Saito, Satoko
Kobayashi, Tadahiro
Takada, Masayuki
Nakane, Masaki
Sakaguchi, Kento
Tanaka, Ken
Takahashi, Kazunori
Kawamae, Kaneyuki
Author_xml – sequence: 1
  givenname: Tadahiro
  surname: Kobayashi
  fullname: Kobayashi, Tadahiro
  email: *Tadahiro Kobayashi, ta-kobayashi@med.id.yamagata-u.ac.jp
– sequence: 2
  givenname: Satoko
  surname: Saito
  fullname: Saito, Satoko
– sequence: 3
  givenname: Masayuki
  surname: Takada
  fullname: Takada, Masayuki
– sequence: 4
  givenname: Kento
  surname: Sakaguchi
  fullname: Sakaguchi, Kento
– sequence: 5
  givenname: Kazunori
  surname: Takahashi
  fullname: Takahashi, Kazunori
– sequence: 6
  givenname: Ken
  surname: Tanaka
  fullname: Tanaka, Ken
– sequence: 7
  givenname: Kaneyuki
  surname: Kawamae
  fullname: Kawamae, Kaneyuki
– sequence: 8
  givenname: Masaki
  surname: Nakane
  fullname: Nakane, Masaki
BookMark eNpt0M9LwzAUwPEgCs65g3cPAU8eqvnVpfEipfhjMBHGPJfX_JidsylJ0fnfW-0YHjy98PjwhbwTdNj4xiJ0RskVpam6JoSknKeMHKARS4lIUpZlh3_ex2gS47pnTCpBOB2h2yeIsf6weNZ0fltr6Grf4M-6e8WS4CVUG9tF7B3O23oLFTQ3OMcFRIsXtvWhO0VHDjbRTnZzjF7u75bFYzJ_fpgV-TzRLKUk0SJVkgvJecY4NxysYU5IRZ3hWlYus2YqZWZUaoBqw3sMmRTUUC6Vq4CP0WzoGg_rsg31O4Sv0kNd_i58WJUQulpvbCktMEWnRvS_FI4o0BVzVnNLhMqkZH3rcmjp4GMM1u17lJQ_hyz3h-ztxWDfIKxs2MtikQ-ibI3r1fm_ahf5BleyeMc
Cites_doi 10.1111/jth.12720
10.1016/j.ajem.2016.11.035
10.1080/15563650.2016.1204453
10.1111/bcp.12106
10.1097/MBC.0000000000000706
10.1160/TH17-07-0474
10.1056/NEJMoa1814051
10.1111/ijlh.12640
10.1111/bcp.13790
10.1111/jth.13912
ContentType Journal Article
Copyright 2023 The Author(s). Published by S. Karger AG, Basel
Copyright_xml – notice: 2023 The Author(s). Published by S. Karger AG, Basel
DBID M--
AAYXX
CITATION
DOA
DOI 10.1159/000533520
DatabaseName Karger Open Access
CrossRef
Open Access: DOAJ - Directory of Open Access Journals
DatabaseTitle CrossRef
DatabaseTitleList
CrossRef

Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: M--
  name: Karger Open Access
  url: https://www.karger.com/OpenAccess
  sourceTypes:
    Enrichment Source
    Publisher
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2504-5288
EndPage 18
ExternalDocumentID oai_doaj_org_article_7ea2916d40274f09acb2fec3e0498772
10_1159_000533520
533520
GroupedDBID 0R~
AAJPQ
ABPAZ
AELET
AETAF
AEYAO
ALMA_UNASSIGNED_HOLDINGS
EBS
EMOBN
GROUPED_DOAJ
IAO
IHR
M--
M~E
O9-
OK1
RKO
AAYXX
CITATION
ITC
ID FETCH-LOGICAL-c2510-c4597347338233d3aed2f4791fd3c7bf8ed6778d95da1cd3973a8741d1379fba3
IEDL.DBID DOA
ISSN 2504-5288
IngestDate Tue Oct 22 15:15:51 EDT 2024
Thu Sep 26 21:25:14 EDT 2024
Thu Aug 29 12:04:28 EDT 2024
Sat Aug 31 21:00:32 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Anti-Xa activity
Intoxication
Prothrombin time-international normalized ratio
Antithrombin activity
Apixaban
Language English
License This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c2510-c4597347338233d3aed2f4791fd3c7bf8ed6778d95da1cd3973a8741d1379fba3
OpenAccessLink https://doaj.org/article/7ea2916d40274f09acb2fec3e0498772
PageCount 6
ParticipantIDs doaj_primary_oai_doaj_org_article_7ea2916d40274f09acb2fec3e0498772
crossref_primary_10_1159_000533520
karger_primary_533520
PublicationCentury 2000
PublicationDate 20230912
PublicationDateYYYYMMDD 2023-09-12
PublicationDate_xml – month: 09
  year: 2023
  text: 20230912
  day: 12
PublicationDecade 2020
PublicationPlace Basel, Switzerland
PublicationPlace_xml – name: Basel, Switzerland
PublicationTitle Case reports in acute medicine
PublicationTitleAlternate Case Rep Acute Med
PublicationYear 2023
Publisher Karger Publishers
Publisher_xml – name: Karger Publishers
References Dale BJ, Ginsberg JS, Johnston M, Hirsh J, Weitz JI, Eikelboom JW. Comparison of the effects of apixaban and rivaroxaban on Prothrombin and activated partial thromboplastin times using various reagents. J Thromb Haemost. 2014;12(11):1810–5.
Franck B, Dulaurent S, El Balkhi S, Monchaud C, Picard N, Marquet P. Self-poisoning with 60 tablets of apixaban, a pharmacokinetics case report. Br J Clin Pharmacol. 2019;85(1):270–2.
Guadarrama DS, DeMarinis SM, Sweeney JD. Coagulation assays in a case of apixaban overdose. Blood Coagul Fibrinolysis. 2018;29(2):231–5.
Frost C, Nepal S, Wang J, Schuster A, Byon W, Boyd RA. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol. 2013;76(5):776–86.
Leikin SM, Patel H, Welker KL, Leikin JB. The X factor: lack of bleeding after an acute apixaban overdose. AmJ Emerg Med. 2017355801.e5801.e6.
Mast L, Verheul RJ, Reijnen R, van Rossen RCJM, Overdiek JWPM, Wilms EB. Apixaban auto-intoxication: toxicokinetics and coagulation tests. Thromb Haemost. 2017;117:2209–11.
Douxfils J, Ageno W, Samama CM, Lessire S, Ten Cate H, Verhamme P. Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. J Thromb Haemost. 2018;16(2):209–19.
Van Blerk M, Bailleul E, Chatelain B, Demulder A, Devreese K, Douxfils J. Influence of apixaban on commonly used coagulation assays: results from the Belgian national external quality assessment scheme. Int J Lab Hematol. 2017;39(4):402–8.
Barton J, Wong A, Graudins A. Anti-Xa activity in apixaban overdose: a case report. Clin Toxicol. 2016;54(9):871–3.
Connolly SJ, Crowther M, Eikelboom JW, Gibson CM, Curnutte JT, Lawrence JH. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med. 2019;380(14):1326–35.
ref8
ref7
ref9
ref4
ref3
ref6
ref5
ref10
ref2
ref1
References_xml – ident: ref9
  doi: 10.1111/jth.12720
– ident: ref1
  doi: 10.1016/j.ajem.2016.11.035
– ident: ref2
  doi: 10.1080/15563650.2016.1204453
– ident: ref8
  doi: 10.1111/bcp.12106
– ident: ref5
  doi: 10.1097/MBC.0000000000000706
– ident: ref3
  doi: 10.1160/TH17-07-0474
– ident: ref7
  doi: 10.1056/NEJMoa1814051
– ident: ref10
  doi: 10.1111/ijlh.12640
– ident: ref4
  doi: 10.1111/bcp.13790
– ident: ref6
  doi: 10.1111/jth.13912
SSID ssj0002794031
Score 2.2854123
Snippet Abstract Apixaban is a direct oral anticoagulation agent that exerts its effect through the direct inhibition of factor Xa. We treated a case of massive...
Apixaban is a direct oral anticoagulation agent that exerts its effect through the direct inhibition of factor Xa. We treated a case of massive intoxication...
SourceID doaj
crossref
karger
SourceType Open Website
Aggregation Database
Enrichment Source
Publisher
StartPage 13
SubjectTerms anti-xa activity
antithrombin activity
apixaban
Case Report
intoxication
prothrombin time-international normalized ratio
SummonAdditionalLinks – databaseName: Karger Open Access
  dbid: M--
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV3fS8MwEA6iIL6IPyZOpwTxNdgladP4InU4plAfZIO9lfwUEboxK-zP99J2xQm-pk0K12vv-y657xC69TKGz8ikRDkZE55oRmTkwgEba72OUu5r4fn8NZnM-Ms8nrf5jlAL8xnOP9fSqJ22AATcu6ZmNKZAzveoSHjw35yQLptCwa3APVvpoK0ZWwGn1uWHYNM85lckGR-hwxYC4qx5Z8dox5UnaD9vN7lP0UMOgBZ-Qvi5rBbrNqeGQ8IUiwhPQ61T9YUXHmfLj7XSqrzHGR5BNMINmu6h2fhpOpqQts8BMYAuImI4oHrGBQt7cswy5Sz1XMiht8wI7VNng8yblbFVQ2MBQTCVAhKwQyak14qdod1yUbpzhL2kSmjHPTUuULM0TTwwLpcwn9hI6T662RijWDZyFkVNA2JZdBbro8dgpu6GoEBdDyxW70Xr0IVwigK0tDzwWh9JZTT1zjAHlCMFyN5HvcbI3TKbxQd_xkdvWXOpWFp_8c-0S3QQGr2TunnDAO1Wq293BXCg0te1J_wA1vitRQ
  priority: 102
  providerName: Karger AG
Title Massive Intoxication with 70 Tablets of Apixaban: A Case Report
URI https://karger.com/doi/10.1159/000533520
https://doaj.org/article/7ea2916d40274f09acb2fec3e0498772
Volume 6
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LSwMxEA7iQbyIj4rVKkG8hm432Ue8yFosVVgP0kJvS56gwrbUFfrznSTbsnjx4mUP2SUJM9nMN5nJNwjdWZ7Ab6RyIgxPCEslJTwyLsFGayujnFlPPF--ptM5e1kki06pL5cTFuiBg-CGmRExQBjNnP9kIy6UjK1R1AC0zQEa-t034h1n6sOH0ziD5dpSCYHJHoZbp4mr690xQJ6nH4zPp0u7Xncsy-QYHbWQEBdhKidoz9Sn6KBsg95n6KEEgAubEn6um-WmPWPD7gAVZxGeubtPzRdeWlys3jdCivoeF3gM1gkHdN1D88nTbDwlbd0DogBtREQxQPmUZdTF6KimwujYsoyPrKYqkzY32tG-aZ5oMVIaEAUVOSADPaIZt1LQc7RfL2tzgbDlscikYTZWxrlqeZ5a8MBMSm2qIyH76HYrjGoV6C0q7xYkvNpJrI8enZh2HzhGat8AeqpaPVV_6amPekHIu262nQ9-tY_fivCqWml7-R9jX6FDVyWe-MoPA7TfrL_NNWCJRt74ZQPPkpAf9lfDgg
link.rule.ids 315,783,787,867,2109,27649,27938,27939
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Massive+Intoxication+with+70+Tablets+of+Apixaban%3A+A+Case+Report&rft.jtitle=Case+reports+in+acute+medicine&rft.au=Tadahiro+Kobayashi&rft.au=Satoko+Saito&rft.au=Masayuki+Takada&rft.au=Kento+Sakaguchi&rft.date=2023-09-12&rft.pub=Karger+Publishers&rft.eissn=2504-5288&rft.volume=6&rft.issue=1&rft.spage=13&rft.epage=18&rft_id=info:doi/10.1159%2F000533520&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_7ea2916d40274f09acb2fec3e0498772
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2504-5288&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2504-5288&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2504-5288&client=summon